Deluxe Corp. (DLX) reported a 7% drop in revenue from its legacy check business when it reported third quarter results last month, a near mirror image from the more than 6% jump in overall sales. Deluxe CEO Lee Schram said the small-business services provider is not slamming the door on its declining check business, but using it to open new ones. 'We are putting technology around everything we do with check, automating everything in our plants and giving the banks tools to use and manage and run their programs,' said Schram. 'Then we are trying to gain share both on the small business side where a lot of small business owners are still writing checks, as well as with the banks.' Deluxe reported third-quarter earnings of $56.9 million, or $1.13 per share, on revenue of $439.8. The company said it expects revenue in the range of $456 million to $466 million for the fiscal fourth quarter. Deluxe expects full-year earnings in the range of $4.51 to $4.57 per share, with revenue ranging from $1.77 billion to $1.78 billion. Schram said Deluxe has seen tremendous growth in its small business services segment. Revenue in that division was $289 million in the third quarter, up 3.9% year-over-year due primarily to growth in marketing solutions.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.